Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. - Wikidata - wikimedia - TriplyDB

Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.

Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.

http://www.wikidata.org/entity/Q43053141

about

Autophagy in idiopathic pulmonary fibrosis A reactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor α mTOR: a potential therapeutic target in osteoarthritis?Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma Animal models of systemic sclerosis: their utility and limitations.New molecular medicine-based scar management strategies mTOR inhibition rescues osteopenia in mice with systemic sclerosis.Rapamycin inhibits the production of myofibroblasts and reduces corneal scarring after photorefractive keratectomy.TGFβ- and bleomycin-induced extracellular matrix synthesis is mediated through Akt and mammalian target of rapamycin (mTOR)mTOR Overactivation and Compromised Autophagy in the Pathogenesis of Pulmonary Fibrosis.The Tumor Necrosis Factor Superfamily Molecule LIGHT Promotes Keratinocyte Activity and Skin Fibrosis.Involvement of collagen-binding heat shock protein 47 in scleroderma-associated fibrosis.Metabolic regulation of organelle homeostasis in lupus T cells Local application of rapamycin reduces epidural fibrosis after laminectomy via inhibiting fibroblast proliferation and prompting apoptosis.Transcriptional profiling of rapamycin-treated fibroblasts from hypertrophic and keloid scars.Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations.mTOR Overactivation in Mesenchymal cells Aggravates CCl4- Induced liver Fibrosis.Intestinal Microbiota-Derived GABA Mediates Interleukin-17 Expression during Enterotoxigenic Escherichia coli Infection Agonistic Anti-PDGF Receptor Autoantibodies from Patients with Systemic Sclerosis Impact Human Pulmonary Artery Smooth Muscle Cells Function In Vitro.Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Energy metabolism and rheumatic diseases: from cell to organism Fibroblast autophagy in fibrotic disorders.CD4+ T lymphocytes in lung fibrosis: diverse subsets, diverse functions.Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases.Animal models of scleroderma: current state and recent development.Novel investigational agents for the treatment of scleroderma.The effects of sirolimus on target organs during mesenteric ischemia and reperfusion damage in an experimental rat model.Strategy for treatment of fibrosis in systemic sclerosis: Present and future.Autophagy and Obesity-Related Lung Disease.Autophagy: controlling cell fate in rheumatic diseases.Increased expression of latent TGF-β-binding protein 4 affects the fibrotic process in scleroderma by TGF-β/SMAD signaling.Pathogenesis of systemic sclerosis-current concept and emerging treatments.Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles.Autophagy fosters myofibroblast differentiation through MTORC2 activation and downstream upregulation of CTGF.Localization of ανβ6 integrin-TGF-β1/Smad3, mTOR and PPARγ in experimental colorectal fibrosis.Effects of rapamycin on reduction of peridural fibrosis: an experimental study.Rapamycin inhibits transforming growth factor β-induced peritoneal angiogenesis by blocking the secondary hypoxic response.Failed degradation of JunB contributes to overproduction of type I collagen and development of dermal fibrosis in patients with systemic sclerosis.mTORC1 phosphorylates LARP6 to stimulate type I collagen expression.Cellular and molecular mechanisms of intestinal fibrosis.

P2860

Q21134133-9F2194D9-CE22-4104-AE1C-DD4F409B3D85 Q24339412-20147BAE-0D83-4ACE-81DF-3EB9C09B960B Q28087019-F1605794-9527-4459-9E5A-E934B7F47CB6 Q28264437-4A337D8D-993C-43EE-BDC8-70D7F2001C6C Q28390528-8CDCC9CB-4591-4DC2-B262-43067F5A00AF Q33560989-577B3FF1-98E4-499A-A48F-2F7C02F89283 Q34924612-7283E446-0232-4ECC-B7C3-7086D1CD33AD Q35012339-BC991805-32C3-46AA-A920-F252DE16FF11 Q35041204-C067048A-0A1F-43C1-A908-1D837D853F8A Q35780096-28D9CE87-88BA-4F03-B75F-065766C4AB34 Q35858686-E78E89FC-CB4E-43E3-B073-F335F1D5C3CD Q35862865-341745B0-B372-47BE-9D3A-5399C7DDFDF8 Q36177195-DEFF8B96-3433-4B38-8FD0-92E9D99D28A2 Q36879793-F9B29859-FE6C-406E-99E2-29AD1DF33021 Q36951195-CCCA9440-447E-4A2F-A7CF-D3FDE43AC507 Q37337868-77E110CF-756A-47CD-B78B-E13A1B41A34C Q37397195-ED4D8106-02EC-4D28-953E-62CBB5361E2E Q37587229-5E71183E-9B76-4514-A952-0A482FE2F160 Q37629847-2958CBFF-7F1E-4C56-9C77-4F6E228548F6 Q37649641-A18F4120-4D61-413E-A3B0-1973BB69BDEE Q38022768-D590E542-9C40-4EA8-AC74-AE75DFA5B44B Q38047232-D9C00668-2A70-4B55-9D7D-48C947680438 Q38060461-3F132CC1-0A6F-4EC0-A84E-0BDB21F89C2A Q38154628-B85D90B8-2890-410D-A139-BCC9EF572CEC Q38154834-62495C38-1F6D-402A-B204-B3AC92A974C8 Q38164818-B03C751A-845C-47E6-B1CA-47F43C7038B8 Q38282432-F50FE08A-7C12-4068-AF2F-139D43510FB5 Q38701990-2263D01F-853C-4DAB-B789-5C2D0C902D5A Q38743703-44C4C0E6-4225-494A-9AB0-74E4492A3E8A Q38873681-692B4906-EB1F-45A9-8E62-29E86AADFBF7 Q38927336-6D37401A-097D-4DF4-A763-AC4D0146A4F7 Q39294794-A35E37B2-8418-4167-A12A-2252FEAAF556 Q39321120-34965D4A-E5B0-44C5-AE85-AA16BD92159C Q41619893-10DA8E65-9CEE-4B44-B46B-C3BC64B17897 Q41879637-361668ED-98D2-46AD-8DB1-4BBC7E188A74 Q42013776-4366016E-C549-4F9F-B0B7-EB1152FC19AA Q42073238-E87C3EA8-298A-424E-81DE-2BCF8A320ED1 Q42077845-BF15B6A0-6A54-472D-91B0-5279EFC2FAF8 Q42137246-7B631C63-D4D7-4913-BCDD-2F08298D7FE3 Q42252132-4AC89451-2711-409E-9207-D17B0491E808

P2860

Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.

http://www.wikidata.org/entity/Q43053141

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Treatment with rapamycin preve ...... models of systemic sclerosis.

@en

Treatment with rapamycin preve ...... models of systemic sclerosis.

@nl

type

label

Treatment with rapamycin preve ...... models of systemic sclerosis.

@en

Treatment with rapamycin preve ...... models of systemic sclerosis.

@nl

prefLabel

Treatment with rapamycin preve ...... models of systemic sclerosis.

@en

Treatment with rapamycin preve ...... models of systemic sclerosis.

@nl

P1433

Q43053141-C58213B4-063B-497F-8CF3-4010ECDA077D

P1476

Q43053141-636B8321-ABB0-4DC4-8524-EAA1E01E1136

P2093

Q43053141-43A7EDC1-2C8F-47B1-ADA2-7F1FD86147E9

Q43053141-603FEDAB-26A9-40C4-A3C9-6346EB5E787F

Q43053141-6B5E6733-DF2A-41EB-9920-C61791997E97

Q43053141-7E7DFF50-9A43-4069-BD3B-688FFA6D03B7

Q43053141-7E82850D-C11F-46C7-BF84-D722E12AD8D2

Q43053141-8A4DC191-9D01-49C1-9894-1B28FAE59F88

Q43053141-8A6119D4-8F03-47D5-92C5-31CB39796055

Q43053141-A479E8CA-3915-41BD-8C13-D306EFE7B829

Q43053141-BBA1A0B7-711D-41D9-A863-53FAF294D26C

Q43053141-C423AA8C-9662-43F5-9D0B-252BE73BF505

P2860

Q43053141-15EC0BDB-E472-430C-839D-E1EB56E229D0

Q43053141-6F76931C-C625-4A79-A203-EEB463DF5912

P304

Q43053141-83962E9D-80AB-4496-AA2D-84DDCB09B983

P31

Q43053141-B61DFD9E-0EA0-4B03-8B40-FEDBAFE7E5B5

P356

Q43053141-6D4F011C-03EB-45B4-978B-323718538527

P433

Q43053141-10C44D13-6FC1-4F9B-B631-70F0B24638F7

P478

Q43053141-421B342C-C013-4109-BE72-EA9D46C9546E

P577

Q43053141-27E687CE-457B-4D71-8195-5C5A479EC3B8

P5875

Q43053141-1201D9E2-6F43-401A-A0E7-A0F68C031ECC

P698

Q43053141-0914394E-DF37-4AC5-8241-D35B08874570

P356

P1433

Arthritis & Rheumatology

P1476

Treatment with rapamycin preve ...... models of systemic sclerosis.

@en

P2093

Asako Yoshizaki

http://www.w3.org/2001/XMLSchema#string

Ayumi Yoshizaki

http://www.w3.org/2001/XMLSchema#string

Fumihide Ogawa

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Komura

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Shimizu

http://www.w3.org/2001/XMLSchema#string

Koichi Yanaba

http://www.w3.org/2001/XMLSchema#string

Manabu Fujimoto

http://www.w3.org/2001/XMLSchema#string

Minoru Hasegawa

http://www.w3.org/2001/XMLSchema#string

Motoi Takenaka

http://www.w3.org/2001/XMLSchema#string

Shinichi Sato

http://www.w3.org/2001/XMLSchema#string

P2860

CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse

The p110delta subunit of phosphoinositide 3-kinase is required for the lipopolysaccharide response of mouse B cells.

P304

2476-2487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.27498

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44633989

http://www.w3.org/2001/XMLSchema#string

P698

20506342

http://www.w3.org/2001/XMLSchema#string